Guangzhou, China– August , 2024 – Inc. “The EC approval of BAT2206 is anothersignificant accomplishment for Bio-Thera as it marks Bio-Thera’s third EC approvedproduct” said Shengfeng Li, CEO at Bio-Thera. “Bio-Thera is committed toexpanding access fo...
View DetailsTheclinical comparative study met its primary endpoint and showed similar efficacyand comparable safety profile in patients with moderate to severe plaque psoriasisGUANGZHOU,China, November 29, 2023 /PRNewswire/ -- Bio-Thera Solutions, Ltd. (688177:S...
GUANGZHOU,China, October 24, 2023 -- Bio-Thera Solutions, Ltd (688177:SH), acommercial-stage biopharmaceutical company developing a pipeline of biosimilarsand innovative assets, announced that the National Health Surveillance Agency(“ANVISA”) publish...
TOFIDENCE is Bio-Thera’s first productapproved by USFDA.TOFIDENCE is the first monoclonal antibodydrug researched, developed, and manufactured by a Chinese pharmaceuticalcompany to receive FDA approval in the United StatesTOFIDENCE is the first biosi...
